Whooping cough antigen recombinant expression vector, engineering bacterium and application of whooping cough antigen recombinant expression vector and engineering bacterium

By constructing the Bordetella pertussis ΔPT engineered strain, the production process of pertussis antigen was simplified, solving the problems of cumbersome antigen separation and purification and difficulty in PT protein detoxification in existing technologies. This enabled the production of antigens with high purity and high immunogenicity, while reducing production costs and fermentation time.

CN122256394APending Publication Date: 2026-06-23JIANGSU THERAVAC BIO PHARMA CO LTD
1 Cites 0 Cited by

Patent Information

Application Number
CN202411913707.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-23
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

In the existing pertussis vaccine production process, the separation and purification of pertussis antigen is complicated, which affects the stability of vaccine production. Furthermore, the detoxification treatment of PT protein can easily lead to toxicity reversal, reducing the immunogenicity and purity of FHA.

Method used

We constructed a Bordetella pertussis ΔPT engineered strain, knocked out the PT gene, and simplified the production process of FHA and PRN antigens using a recombinant expression vector for pertussis antigen, avoiding interference from PT protein and maintaining high purity and immunogenicity.

Benefits of technology

The production process of pertussis antigen was simplified, the purity and immunogenicity of FHA and PRN antigens were improved, the risk of PT protein toxicity reversal was avoided, production costs were reduced, and the fermentation cycle was significantly shortened.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a pertussis antigen recombinant expression vector, an engineering bacterium and an application of the pertussis antigen recombinant expression vector and the engineering bacterium. The pertussis antigen recombinant expression vector comprises a resistance screening gene, a pertussis exotoxin gene upstream recombinant nucleic acid fragment and a pertussis exotoxin gene downstream recombinant nucleic acid fragment, wherein the upstream recombinant nucleic acid fragment and the downstream recombinant nucleic acid fragment of the pertussis exotoxin gene can be respectively subjected to homologous recombination with the upstream and the downstream of the pertussis exotoxin gene. According to the invention, bordetella pertussis is taken as a host, and the engineering bacterium delta PT strain for producing FHA and PRN is constructed by knocking out a PT gene, so that the production process of FHA and PRN antigens is simplified, the relatively high purity and immunogenicity of the FHA and PRN antigens are maintained, the interference of PT protein during production of the FHA and PRN antigens is eliminated, a PT protein detoxification process is avoided, and the production cost is reduced. And the possible risk of PT protein toxicity reversion is avoided.
Need to check novelty before this filing date? Find Prior Art